Betta Pharmaceuticals Co Ltd (SHE:300558) — Market Cap & Net Worth
Market Cap & Net Worth: Betta Pharmaceuticals Co Ltd (300558)
Betta Pharmaceuticals Co Ltd (SHE:300558) has a market capitalization of $3.20 Billion (CN¥21.85 Billion) as of May 2, 2026. Listed on the SHE stock exchange, this China-based company holds position #4750 globally and #878 in its home market, demonstrating a 17.59% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Betta Pharmaceuticals Co Ltd's stock price CN¥51.94 by its total outstanding shares 420733843 (420.73 Million). Analyse how efficiently does Betta Pharmaceuticals Co Ltd generate cash to see how efficiently the company converts income to cash.
Betta Pharmaceuticals Co Ltd Market Cap History: 2016 to 2026
Betta Pharmaceuticals Co Ltd's market capitalization history from 2016 to 2026. Data shows growth from $4.43 Billion to $3.20 Billion (8.16% CAGR).
Index Memberships
Betta Pharmaceuticals Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ChiNext
CNT
|
$1.31 Trillion | 0.24% | #70 of 100 |
Weight: Betta Pharmaceuticals Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Betta Pharmaceuticals Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Betta Pharmaceuticals Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.15x
Betta Pharmaceuticals Co Ltd's market cap is 1.15 times its annual revenue
Latest Price to Earnings (P/E) Ratio
8.25x
Betta Pharmaceuticals Co Ltd's market cap is 8.25 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.43 Billion | $1.04 Billion | $368.80 Million | 4.28x | 12.02x |
| 2017 | $3.81 Billion | $1.03 Billion | $257.73 Million | 3.72x | 14.80x |
| 2018 | $1.93 Billion | $1.22 Billion | $166.82 Million | 1.58x | 11.58x |
| 2019 | $3.98 Billion | $1.55 Billion | $230.82 Million | 2.56x | 17.24x |
| 2020 | $6.51 Billion | $1.87 Billion | $606.36 Million | 3.48x | 10.74x |
| 2021 | $4.86 Billion | $2.25 Billion | $383.07 Million | 2.16x | 12.68x |
| 2022 | $3.02 Billion | $2.38 Billion | $145.42 Million | 1.27x | 20.74x |
| 2023 | $3.16 Billion | $2.46 Billion | $348.03 Million | 1.29x | 9.08x |
| 2024 | $3.32 Billion | $2.89 Billion | $402.57 Million | 1.15x | 8.25x |
Competitor Companies of 300558 by Market Capitalization
Companies near Betta Pharmaceuticals Co Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Betta Pharmaceuticals Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Betta Pharmaceuticals Co Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Betta Pharmaceuticals Co Ltd's market cap moved from $4.43 Billion to $ 3.20 Billion, with a yearly change of 8.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥3.20 Billion | +11.24% |
| 2025 | CN¥2.87 Billion | -13.42% |
| 2024 | CN¥3.32 Billion | +5.09% |
| 2023 | CN¥3.16 Billion | +4.78% |
| 2022 | CN¥3.02 Billion | -37.93% |
| 2021 | CN¥4.86 Billion | -25.42% |
| 2020 | CN¥6.51 Billion | +63.72% |
| 2019 | CN¥3.98 Billion | +106.05% |
| 2018 | CN¥1.93 Billion | -49.37% |
| 2017 | CN¥3.81 Billion | -13.95% |
| 2016 | CN¥4.43 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Betta Pharmaceuticals Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.20 Billion USD |
| MoneyControl | $3.20 Billion USD |
| MarketWatch | $3.20 Billion USD |
| marketcap.company | $3.20 Billion USD |
| Reuters | $3.20 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Betta Pharmaceuticals Co Ltd
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor fo… Read more